22 November 2004
Welcome to the November edition of Clayton Utz Life Sciences Insights. In this edition we look at the proposal to require manufacturers' details on medicines, and what's next in labeling regulation.
We'll also find out the latest in the development of a national regulatory framework for human cell and tissue therapies, and the regulatory problems surrounding gene patenting.
Finally, we'll look at the draft Code which helps listed biotech companies make disclosures as required by the ASX.
By Robyn Baker and Janine Jansen.
By Robyn Baker and Mia Livingstone .
The Pan recall revealed some of the problems with our current labelling system. The work done by the Therapeutic Goods Committee on the possible mandatory inclusion of manufacturers' names on medicines will play a part in the review of these issues presently being conducted by an expert Committee on Medicine Labelling, say Robyn Baker and Mia Livingstone.
By Anna Sharpe and Georgina Johnson.
